No, we do not currently have human clinical trials showing GLP one
Get Physician-Supervised Peptide Therapy Understanding side effects is important to safe peptide use
In two Phase 3 studies, a fixed-dose combination of cagrilintide and semaglutide (each at 2.4 mg) was associated with weight reductions of 20.4% and 10.4% (placebo subtracted) after once-weekly subcutaneous injection for 68 weeks in overweight/obese individuals without and with type 2 diabetes, respectively (Table 2) [68]
Leptin, implicated in inflammatory, mitogenic, and pro-angiogenic pathways, has been associated with breast cancer development, with studies indicating that inhibiting leptin signaling reduces the growth of breast cancer induced by carcinogens [12]
There have, however, been drugs that offer promise